Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA

Stock Track

Apr 15

Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.

The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.

This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1184551801"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184551801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184551801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184551801","market":"us","top_or_hot":-1,"title":"Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA","media":"Stock Track","content":"<p>Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.</p>\n<p>The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.</p>\n<p>This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Clarity Pharmaceuticals Soars 5.15% Intraday on Commercial Manufacturing Deal for Cu-64 SAR-bisPSMA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.</p>\n<p>The company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.</p>\n<p>This manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1184551801","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184551801","pubTimestamp":1776211595,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Clarity Pharmaceuticals盘中大涨5.15%CU-64 SAR-BiPSMA商业制造交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":1},"content_text":"Clarity Pharmaceuticals Ltd (CU6.AU) saw its stock price soar 5.15% during intraday trading on Wednesday, following the announcement of a significant commercial manufacturing agreement.\nThe company signed a deal with Nucleus RadioPharma for the manufacturing of Cu-64 SAR-bisPSMA. The agreement covers Nucleus's facility in Rochester, Minnesota, which has a capacity of approximately 50,000 patient doses per year. It also includes a planned site in Spring House, Pennsylvania, targeted to open in 2028 with a capacity of up to 600,000 doses per year.\nThis manufacturing network is positioned to support the anticipated commercial launch of Cu-64 SAR-bisPSMA following the completion of Phase III trials (AMPLIFY and CLARIFY) and pending FDA New Drug Application approval. The commercial contract took effect on April 14, 2026, the day prior to the stock's movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}